长期住院精神分裂症患者身体质量指数现况
|
摘要
目的了解长期住院精神分裂症患者身体质量指数现况并分析相关因素。方法选择2018年6月6日14时在宜昌市精神卫生中心住院超过12个月及以上的患者,均规律服药,餐饮由医院食堂统一配送。符合ICD-10精神分裂症的诊断标准,男女不限。于当日测量其身高及体质量,并采用自制表格记录年龄、性别、文化程度、婚姻状况、病程、住院时间等一般信息及用药情况。结果共入组190例患者,有67例(35.26%)服用氯氮平治疗,身体质量指数(body mass index,BMI)超过正常值的有88例(46.32%);服用氯氮平的患者中BMI超重的人数显著高于未服用氯氮平者;另外以BMI是否超重为自变量,是否服用氯氮平为协变量进行二元Logistic回归分析发现,是否服用氯氮平是患者BMI超重的危险因素(P=0.02);经Pearson相关分析发现,BMI与年龄、总病程、住院天数未见相关性。结论多数精神分裂症患者最终合并氯氮平治疗,长期住院精神分裂症患者中BMI超重的发生率远高于普通人群,氯氮平有增加精神分裂症患者BMI超重的风险。
Objective To study the BMI of inpatients whit schizophrenia who is long-term hospitalization and analyze related factors. Methods Patients who were hospitalized for more than 12 months at the Yichang Mental Health Center were given regular medications at 14:00 on June 6,2018. The catering was delivered by the hospital canteen. The schizophrenia inpatients are all meet the diagnostic criteria of ICD-10. The height and weight were measured on the same day, and the general information and medication status such as age, gender, education level, marital status,duration of illness, and length of hospital stay were recorded using a selfmade scale. Results A total of 190 patients were enrolled, 67 cases(35.26%)were treated with clozapine, and 88 cases(46.32%) had a body mass index(BMI) exceeding the normal value; BMI was overweight in patients taking clozapine. The number of patients was significantly higher than those who did not take clozapine. In addition, whether BMI was overweight or not, whether to take clozapine as a covariate for binary logistic regression analysis found that taking clozapine was a risk factor for overweight BMI in patients(P=0.02); Pearson correlation analysis found that BMI was not associated with age, total duration, and length of hospital stay. Conclusion Most patients with schizophrenia are eventually treated with clozapine. The incidence rate of increased BMI in long-term hospitalized schizophrenia patients is much higher than that of the general population. Clozapine may increase the incidence of increased BMI in patients with schizophrenia.
Objective To study the BMI of inpatients whit schizophrenia who is long-term hospitalization and analyze related factors. Methods Patients who were hospitalized for more than 12 months at the Yichang Mental Health Center were given regular medications at 14:00 on June 6,2018. The catering was delivered by the hospital canteen. The schizophrenia inpatients are all meet the diagnostic criteria of ICD-10. The height and weight were measured on the same day, and the general information and medication status such as age, gender, education level, marital status,duration of illness, and length of hospital stay were recorded using a selfmade scale. Results A total of 190 patients were enrolled, 67 cases(35.26%)were treated with clozapine, and 88 cases(46.32%) had a body mass index(BMI) exceeding the normal value; BMI was overweight in patients taking clozapine. The number of patients was significantly higher than those who did not take clozapine. In addition, whether BMI was overweight or not, whether to take clozapine as a covariate for binary logistic regression analysis found that taking clozapine was a risk factor for overweight BMI in patients(P=0.02); Pearson correlation analysis found that BMI was not associated with age, total duration, and length of hospital stay. Conclusion Most patients with schizophrenia are eventually treated with clozapine. The incidence rate of increased BMI in long-term hospitalized schizophrenia patients is much higher than that of the general population. Clozapine may increase the incidence of increased BMI in patients with schizophrenia.
引文
[1]王勋,马宁,王立英,等.2016年全国严重精神障碍患者管理治疗现状分析[J].中华精神科杂志,2018,51(1):47-52.
[2]范肖东,汪向东,于欣,等.ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993:72-81.
[3]Darcia AE,Cavus SY,Dibaz N,et al.Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and in their siblings[J].Schizophrenia Research,2015,166(1):201-206.
[4]牛学虹.精神分裂症与代谢综合征相关性研究进展[J].中国处方药,2017,15(7):10-12.
[5]叶飞英,刘湘鹏,刘月霞,等.长期住院精神分裂症患者伴发代谢综合征情况及相关因素分析[J].四川精神卫生,2015,28(1):48-50.
[6]钟远惠,谢穗峰,喻俊,等.780例长期住院精神分裂症患者代谢综合征患病调查[J].现代临床医学,2017,43(2):105-107.
[7]王红,于纪泽,张芸.长期住院精神分裂症患者中心性肥胖发病率相关因素调查[J].中国民康医学,2014,26(2):48-50.
[8]Dayabandara M,Hanwella R,Ratnatunga S,et al.Antipsychoticassociated weight gain:management strategies and impact on treatment adherence[J].Neuropsychiatr Dis Treat,2017,13:2231-2241.
[9]杨琳,施慎逊,陈剑华,等.氯氮平治疗精神分裂症引发代谢综合征危险因素研究[J].精神医学杂志,2014,27(2):81-84.
[10]谢筠,葛红敏,张旭,等.阿立哌唑与氯氮平治疗精神分裂症的临床疗效对比观察[J].国际精神病学杂志,2018,45(1):39-41.
[11]蔡东滨,杨欣湖,郑伟,等.金刚烷胺治疗奥氮平所致精神分裂症患者体质量增加的Meta分析[J].四川精神卫生,2017,30(3):243-247.
[12]付艳梅,陈尚周.二甲双胍治疗抗精神病药物所致体质量增加和血糖异常的研究进展[J].四川医学,2017,38(12):1451-1453.
[13]杨欣湖,蔡东滨,郑伟,等.防治氯氮平所致体质量增加的研究进展[J].中国健康心理学杂志,2018,26(1):147-151.
[14]樊凤英.康复护理对长期住院精神分裂症患者社会功能影响的对照研究[J].中国继续医学教育,2017,9(24):210-211.
[15]许敏,吴桐,肖燕,等.运动疗法对慢性精神分裂症患者心电图和体质量指数的影响[J].中西医结合护理(中英文),2018,4(2):131-133.
[2]范肖东,汪向东,于欣,等.ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993:72-81.
[3]Darcia AE,Cavus SY,Dibaz N,et al.Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and in their siblings[J].Schizophrenia Research,2015,166(1):201-206.
[4]牛学虹.精神分裂症与代谢综合征相关性研究进展[J].中国处方药,2017,15(7):10-12.
[5]叶飞英,刘湘鹏,刘月霞,等.长期住院精神分裂症患者伴发代谢综合征情况及相关因素分析[J].四川精神卫生,2015,28(1):48-50.
[6]钟远惠,谢穗峰,喻俊,等.780例长期住院精神分裂症患者代谢综合征患病调查[J].现代临床医学,2017,43(2):105-107.
[7]王红,于纪泽,张芸.长期住院精神分裂症患者中心性肥胖发病率相关因素调查[J].中国民康医学,2014,26(2):48-50.
[8]Dayabandara M,Hanwella R,Ratnatunga S,et al.Antipsychoticassociated weight gain:management strategies and impact on treatment adherence[J].Neuropsychiatr Dis Treat,2017,13:2231-2241.
[9]杨琳,施慎逊,陈剑华,等.氯氮平治疗精神分裂症引发代谢综合征危险因素研究[J].精神医学杂志,2014,27(2):81-84.
[10]谢筠,葛红敏,张旭,等.阿立哌唑与氯氮平治疗精神分裂症的临床疗效对比观察[J].国际精神病学杂志,2018,45(1):39-41.
[11]蔡东滨,杨欣湖,郑伟,等.金刚烷胺治疗奥氮平所致精神分裂症患者体质量增加的Meta分析[J].四川精神卫生,2017,30(3):243-247.
[12]付艳梅,陈尚周.二甲双胍治疗抗精神病药物所致体质量增加和血糖异常的研究进展[J].四川医学,2017,38(12):1451-1453.
[13]杨欣湖,蔡东滨,郑伟,等.防治氯氮平所致体质量增加的研究进展[J].中国健康心理学杂志,2018,26(1):147-151.
[14]樊凤英.康复护理对长期住院精神分裂症患者社会功能影响的对照研究[J].中国继续医学教育,2017,9(24):210-211.
[15]许敏,吴桐,肖燕,等.运动疗法对慢性精神分裂症患者心电图和体质量指数的影响[J].中西医结合护理(中英文),2018,4(2):131-133.